Epic Research is a leading financial services provider with presence in Indian and other global capital markets. Provides Stock Tips, Forex Tips, Commodity Tips, MCX Tips, Equity Tips, Tips, Intraday Tips, NSE Tips, BSE Tips, COMEX Tips, PCG Pack and NCDEX Tips. We provide services in equity, commodity and Forex market.

1. HEADLINES
 Indian Market
Indian equity markets ended flat.
Nifty down by 1.15 pts and settle at
5626.60
Sensex down by 10.77 pts at 18506.57.
Bank Nifty down by 32.55 pts at
11475.80
DAILY EQUITY  Global Market
NEWSLETTER European markets were up with FTSE
TH up by 6.87 pts at 5797,CAC down by 3497
26 NOVEMBER 2012
pts and DAX up by 1.00 pts at 7245.99
Dow future up by 22.00 pts at 12822.00
 HEADLINES
• SEBI seeks info on IPO probe, warns
penalty against DLF
• Ranbaxy recalls Atorvastatin from US
market, stock slips 2%
• Siemens Q4 PAT seen up 9% at Rs 195
crore
• Nifty ends flat; Hindustan Copper, Blue
Dart offers fully subscribed
WWW.EPICRESEARCH.CO 09752199966

2.  MARKET ANALYSIS:
 Key benchmark indices registered small losses in choppy trading sessions. The market breadth was
negative. The barometer index, BSE Sensex, lost 10.77 points or 0.06%, up close to 105 points from
the day's low and off close to 50 points from the day's high. Index heavyweight and cigarette maker
ITC edged lower. Another index heavyweight Reliance Industries (RIL) edged higher. Realty stocks
edged lower. In banking pack, HDFC Bank hit record high. Aviation shares surged. Ranbaxy
Laboratories declined after the company said it has made a recall of Atorvastatin from the US market
which will cause temporary disruption to that market of this product.The BSE Sensex was up 48.15
points or 0.26% to 18,508.53.
 The S&P CNX Nifty shed 1.15 points or 0.02% to 5,626.60,
 From the 30-share Sensex pack, 18 stocks fell while the rest of them rose.
 CICI Bank fell 0.72%. ICICI Bank's net profit jumped 30% to Rs 1956 crore in Q2 September 2012
over Q2 September 2011. Net interest income jumped 35% to Rs 3371 crore and non-interest income
jumped 17% to Rs 2043 crore in Q2 September 2012 over Q2 September 2011. Net interest margin
improved to 3% in Q2 September 2012 from 2.61% in Q2 September 2011. Cost-to-income ratio
reduced to 40.9% in Q2 September 2012 from 44.4% in Q2 September 2011. The result was
announced on 26 October 2012.of India, and Bank of Baroda gained by between 0.38% to 1.65% Tyre
shares gained across the board. Apollo Tyres, JK Tyre & Industries, MRF and CEAT rose by between
0.51% to 3.05%.
STOCKS TO WATCH
 FII’s and DII’s  HEXAWARE
CATEGORY DATE BUY SELL NET  JP ASSOSIATE
23-Nov-2012 1736.16 1369.79 366.37  EXIDE
FII
23-Nov-2012 532.64 716.91 -184.27  IRB INFRA
DII
SCRIPS IN BAN PERIOD
 NIFTY DAILY PIVOTS
 SUZLON
PIVOT R4 R3 R2 R1 PP S1 S2 S3 S4
NIFTY 5775 5725 5625 5652 5624 5602 5574 5524 5474  PUNJLYOD
 WELCORP
 HDIL
 RENUKA
WWW.EPICRESEARCH.CO 09752199966

3. .
 GAINERS AND LOOSERS
EXPERT OPINION
NIFTY
DAILY NIFTY GAINERS
 Nifty looks Consolidated
SCRIPS RATE VOL. PR. NET %  Strategy: Buy on dips
(000) CLOSE CHAN CHANG
GE E  Support:5602
Asian 4054.1 75.8 3968.05 86.05 2.17  Resistance: 5652
Paints
BHEL 224.7 2438.12 221.3 3.4 1.54 BANK NIFTY
 Bank Nifty looks consolidated
HCL 636.45 1746.31 627.3 9.15 1.46
Tech.  Strategy: Buy on dips
Hero 1825.25 211.3 1803.3 21.95 1.22
MotoCo.  Support:11413
530.2 1034.97 524.35 5.85 1.12  Resistance:11571
Hindusta
n 
Unilever
PREVIOUS PERFORMANCE
TYPE SCRIP B/S RESULT
DAILY NIFTY LOOSERS
NOT
SCRIPS RATE VOL. PR. NET % CASH APTECH S
EXECUTED
(000) CLOSE CHAN CHA JP NOT
CASH B
GE NGE ASSOCIATE EXECUTED
Ranbaxy 495.95 191.81 512.7 -16.75 -3.27 TGT
FUTURE AMBUJA B
Labs. ACHEIVED
NTPC 159.5 662.71 163.7 -4.2 -2.57 TATA TGT
FUTURE S
MOTORS ACHEIVED
Grasim 3179.15 3.49 3243.8 -64.65 -1.99
Industries
GAIL India 340 35.59 346.75 -6.75 -1.95
NMDC 166.5 48.77 169.7 -3.2 -1.89
09752199966

4. MARKET CALLS
CASH
ST ND
SCRIPS ACTION LEVEL 1 TARGET 2 TARGET STOP LOSS
EXIDE BUY 140.10 141.20 143.30 138.95
HEXAWARE SELL 100.90 100 99 101.80
FUTURE
ST ND
SCRIPS ACTION LEVEL 1 TARGET 2 TARGET STOP LOSS
.
IRB INFRA BUY 123.40 124.40 125.90 122.40
JP ASSOSIATE SELL 88.50 88 87.30 89.05
Disclaimer
The information and views in this report, our website & all the service we provide are believed to be reliable, but we do not accept any
responsibility (or liability) for errors of fact or opinion. Users have the right to choose the product/s that suits them the most.
Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on
sources that we consider reliable.
This material is for personal information and based upon it & takes no responsibility
The information given herein should be treated as only factor, while making investment decision. The report does not provide individually
tailor-made investment advice. Epic research recommends that investors independently evaluate particular investments and strategies, and
encourages investors to seek the advice of a financial adviser. Epic research shall not be responsible for any transaction conducted based on
the information given in this report, which is in violation of rules and regulations of NSE and BSE.
The share price projections shown are not necessarily indicative of future price performance. The information herein, together with all
estimates and forecasts, can change without notice. Analyst or any person related to epic research might be holding positions in the stocks
recommended. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views
expressed as a recommendation for which either the site or its owners or anyone can be held responsible for . Any surfing and reading of
the information is the acceptance of this disclaimer.
All Rights Reserved. Investment in equity & bullion market has its own risks.
We, however, do not vouch for the accuracy or the completeness thereof. we are not responsible for any loss incurred whatsoev er for any
financial profits or loss which may arise from the recommendations above epic research does not purport to be an invitation or an offer to
buy or sell any financial instrument. Our Clients (Paid Or Unpaid), Any third party or anyone else have no rights to forward or share our calls
or SMS or Report or Any Information Provided by us to/with anyone which is received directly or indirectly by them. If found so then Serious
Legal Actions can be taken.